Piper Sandler analyst Biren Amin discusses recent news in ATTR cardiomyopathy, ophthalmology, Duchenne muscular dystrophy, and more

blonca9
Oct 22, 2024
1 min read

Biren Amin joins BiotechTV from the NYSE and discusses BridgeBio, Ocular Therapeutix, Apellis, Sarepta, Solid Bio, Cargo Therapeutics, Allogene, Arcellx, and Elevation Oncology, and more.

Recent Posts

See All

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover

Piper Sandler analyst Biren Amin discusses recent news in ATTR cardiomyopathy, ophthalmology, Duchenne muscular dystrophy, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight